Stand Up To Cancer® (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a ...

Stand Up To Cancer (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a combination of two types of targeted therapies, teclistamab and daratumumab, to ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

Equecabtagene autoleucel produced “remarkable” responses in patients whose disease progressed after prior BCMA CAR T-cell therapy, researchers reported.

During today's call, we will be making forward-looking statements, which are subject to risks and uncertainties that may ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Hello, ladies and gentlemen, and welcome to the Autolus ...

As the second leading cause of cancer deaths and the fifth most common cancer ... The global prevalence of blood cancers, including leukemia, lymphoma, and multiple myeloma, continues to rise. Blood ...

Detailed price information for Adaptive Biotechnologies Corp (ADPT-Q) from The Globe and Mail including charting and trades.

Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...